Ginkgo Bioworks, a biotech company founded in 2009 by scientists from MIT, raised $290m in Series E financing round with participation from all existing major investors and other new investors including funds and accounts advised by T. Rowe Price Associates. The latest round of funding will be used to further expand the reach of Ginkgo's platform for cell programming, enabling greater access to the expertise, scale, resources, and technology needed to effectively harness the power of biology.